+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pediatric Vaccines Market by Vaccine Type, Disease, Distribution Channel, End User, Technology, Age Group - Global Forecast to 2030- Product Image
Pediatric Vaccines Market by Vaccine Type, Disease, Distribution Channel, End User, Technology, Age Group - Global Forecast to 2030- Product Image
Sale

Pediatric Vaccines Market by Vaccine Type, Disease, Distribution Channel, End User, Technology, Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968566
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pediatric Vaccines Market grew from USD 21.26 billion in 2024 to USD 23.83 billion in 2025. It is expected to continue growing at a CAGR of 11.61%, reaching USD 41.11 billion by 2030.

Navigating the Future of Pediatric Immunization with Confidence

The pediatric vaccine market stands at a pivotal juncture, driven by a confluence of scientific breakthroughs, shifting public health priorities, and evolving global policy frameworks. As immunization programs expand to cover broader age groups and a wider range of diseases, stakeholders from manufacturers to healthcare providers face mounting pressure to innovate while ensuring equitable access. The accelerating pace of technological advancement, coupled with heightened awareness of vaccine-preventable illnesses, underscores the urgency of a rigorous strategic approach that balances innovation with operational resilience.

This executive summary synthesizes critical findings across multiple domains, offering decision-makers a clear lens through which to examine current trajectories and future opportunities. By unpacking transformative shifts, analyzing the ramifications of new tariff regimes, and exploring granular segmentation and regional dynamics, this overview equips industry leaders with actionable insights. The objective is to foster an integrated understanding of market forces that shape pediatric immunization and to guide strategic investments in research, production, and distribution.

Unprecedented Forces Reshaping Pediatric Vaccine Development

The landscape of pediatric vaccines is undergoing unprecedented transformation propelled by technological innovation, regulatory evolution, and shifting epidemiological patterns. Breakthroughs in conjugate and recombinant platforms are enabling more robust, broad-spectrum formulations that target multiple pathogens within a single dosage. Simultaneously, the advent of novel adjuvant systems and delivery mechanisms is enhancing immunogenicity and improving patient adherence through reduced schedules and less invasive administration.

Regulatory bodies are adapting to this rapid progression by streamlining approval pathways, emphasizing real-world evidence, and encouraging adaptive trial designs. Public-private partnerships have expanded, fostering collaborative frameworks that accelerate research and ensure supply chain security. At the same time, heightened global health initiatives are reshaping funding priorities, with an increasing emphasis on preventive care in low- and middle-income regions. As market participants navigate these transformative currents, the ability to anticipate policy shifts and leverage emerging technologies will be paramount to sustaining competitive advantage and advancing pediatric health outcomes.

Ripple Effects of New Tariffs on United States Vaccine Supply Chain

The imposition of new tariffs by the United States on components critical to vaccine manufacturing has introduced complex challenges across the pediatric immunization supply chain. Tariffs on active pharmaceutical ingredients and specialized packaging materials have elevated production costs, compelling manufacturers to reassess procurement strategies and explore regional sourcing alternatives. Equipment and consumable levies have amplified price pressures, creating ripple effects that extend through distribution networks and ultimately impact end-user pricing structures.

These fiscal barriers have prompted a strategic recalibration within the industry. Some organizations are investing in onshore production capacities to mitigate exposure to import duties, while others are renegotiating supplier agreements and exploring consortium-based sourcing models. The cumulative impact has been a reconfiguration of global trade flows, with emerging markets adapting to supply divergences and developed markets grappling with cost pass-through and reimbursement negotiations. Against this backdrop, stakeholders must remain agile in navigating policy developments, balancing short-term cost fluctuations with long-term commitments to immunization coverage and public health objectives.

Deep Dive into Market Segmentation Driving Pediatric Vaccine Demand

A nuanced understanding of pediatric vaccine demand emerges from a deep dive into six distinct segmentation dimensions. When examined through the prism of vaccine type, predominant formulations span hexavalent offerings designed to protect against multiple diseases in a single regimen, monovalent options tailored to specific pathogens, pentavalent compositions that address five targets simultaneously, and quadrivalent vaccines engineered to confer immunity against four threats. Disease-based segmentation further refines market focus, encompassing traditional diphtheria, pertussis, and tetanus vaccines, hepatitis B immunizations, Haemophilus influenzae type B preparations, measles inoculations, pneumococcal polysaccharide and conjugate variants, poliovirus preventatives, and rotavirus interventions.

Distribution channels distinguish between privately administered doses, dispensed through hospital pharmacies, retail outlets, and specialized clinical settings, and publicly funded programs delivered via donor-supported initiatives and government immunization schedules. End-user categories capture the spectrum of administration points, from general and specialty clinics to both private and public hospitals, dedicated immunization centers, and pharmacies housed within hospital systems or operating independently. Technological segmentation sheds light on the underlying bioprocessing landscape, revealing the prominence of conjugate approaches-either polysaccharide or protein conjugation-inactivated technologies featuring toxoid or viral inactivation protocols, live attenuated platforms encompassing bacterial and viral strains, recombinant methods leveraging mammalian cell culture or yeast based systems, and subunit constructs differentiated into peptide and protein subunits. Finally, age-group segmentation highlights tailored strategies for neonates, infants, toddlers, children, and adolescents, reflecting varied immunogenic profiles and schedule requirements across developmental stages.

Regional Dynamics Influencing Pediatric Vaccine Accessibility

Regional dynamics play a decisive role in shaping pediatric vaccine accessibility and uptake. In the Americas, established immunization infrastructures and robust private-sector channels enable rapid deployment of advanced formulations, though varied reimbursement landscapes across North and South America introduce complexity for manufacturers seeking uniform market entry. Latin American initiatives, supported by multilateral agencies, strive to expand coverage in underserved populations, bridging gaps through tiered pricing and strategic procurement alliances.

Across Europe, the Middle East, and Africa, divergent regulatory frameworks and heterogeneous healthcare financing models influence both market adoption and innovation pathways. Western Europe’s centralized approval mechanisms contrast with more fragmented systems in Eastern regions, while Gulf Cooperation Council states pursue ambitious immunization targets through public-private collaborations. Sub-Saharan Africa and North Africa present unique challenges related to cold-chain infrastructure and fiscal constraints, prompting innovative distribution models and localized manufacturing partnerships.

In the Asia-Pacific arena, soaring demand coincides with rapid expansion of domestic vaccine producers in emerging economies. Public sector procurement dominates established markets like Japan and Australia, whereas India and China leverage scale and cost efficiencies to become global suppliers. Southeast Asia’s diverse health priorities and dynamic urbanization patterns further underscore the need for tailored strategies that align with both national immunization plans and donor-driven programs.

Strategic Moves by Leading Players in the Pediatric Vaccine Arena

Major pharmaceutical corporations continue to shape the pediatric vaccine market through sustained research investment, strategic acquisitions, and global partnership networks. Leading entities have expanded combined offerings by integrating novel antigen targets into established platforms, thereby reinforcing portfolio breadth. Collaborative ventures between multinational firms and specialized biotech companies are accelerating the translation of early-stage innovations into late-phase clinical development, ensuring a steady pipeline of next-generation formulations.

In parallel, emerging manufacturers from Asia have secured key supply agreements with international agencies, leveraging cost-competitive production capabilities to gain market footholds. Their agility in technology adoption and scale-up processes has introduced new sources of competition, compelling legacy players to optimize manufacturing efficiencies and differentiate through value-added services. Moreover, cross-sector alliances between vaccine producers and digital health firms are enhancing post-market surveillance, enabling real-time safety monitoring and fostering greater trust among healthcare professionals and recipients alike.

Actionable Strategies for Strengthening Market Position

To maintain and strengthen market positioning, industry leaders should prioritize integrated strategies that balance innovation with operational excellence. Establishing strategic partnerships across the value chain can secure critical inputs and amplify distribution reach, particularly when forging alliances with government immunization programs and non-governmental organizations. By co-investing in local manufacturing capabilities, organizations can mitigate tariff impacts and increase supply resilience in key geographies.

Simultaneously, engaging proactively with regulatory bodies to adopt adaptive trial designs and fast-track approval mechanisms will accelerate time to market for novel vaccines. Embracing digitization, from end-to-end supply chain visibility to digital immunization records, will enhance patient adherence and streamline logistics. Companies should diversify portfolios across multiple technologies and age segments, ensuring a balanced mix of high-margin combination vaccines and affordable standalone products. Finally, fostering transparent communication and community engagement programs will be essential to counter vaccine hesitancy and to reinforce the societal value proposition of pediatric immunization.

Rigorous Methodology Underpinning Our Analysis

This analysis integrates both qualitative and quantitative methodologies to deliver a comprehensive view of the pediatric vaccine landscape. Primary research involved structured interviews with key opinion leaders, including immunologists, procurement directors, and public health officials, to capture nuanced perspectives on emerging trends and operational challenges. Complementary surveys provided quantitative insights into volume dynamics across distribution channels, while field observations in select high-priority markets offered real-world validation of logistical bottlenecks.

Secondary research drew from an extensive review of peer-reviewed journals, regulatory filings, industry white papers, and proprietary databases, ensuring a robust foundation of evidence. Market intelligence was further enriched by tracking competitive intelligence databases and trade press updates. Analytical techniques such as scenario mapping and sensitivity analysis were employed to elucidate the potential impact of policy shifts, technological breakthroughs, and supply chain disruptions. Rigorous data triangulation and cross-verification protocols underpin the credibility of all findings presented herein.

Synthesizing Insights to Chart the Path Forward

The pediatric vaccine market is characterized by dynamic innovation, evolving regulatory landscapes, and complex regional variations. The insights presented in this summary underscore the critical importance of embracing technological advances, forging resilient partnerships, and navigating policy changes with strategic foresight. Stakeholders who integrate segmentation intelligence with regional and company-level analyses will be best positioned to anticipate shifts in demand and to tailor their offerings accordingly.

As the industry continues to evolve, proactive engagement across public and private sectors, coupled with agile operational models, will be instrumental in addressing both established and emerging immunization needs. By harnessing the strategic recommendations outlined, decision-makers can drive meaningful progress toward global pediatric health goals and unlock sustainable growth opportunities in this vital market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Hexavalent
    • Monovalent
    • Pentavalent
    • Quadrivalent
  • Disease
    • DTP
      • Diphtheria
      • Pertussis
      • Tetanus
    • Hepatitis B
    • Hib
    • Measles
    • Pneumococcal
    • Polio
    • Rotavirus
  • Distribution Channel
    • Private Sector
      • Hospital Pharmacy
      • Retail Pharmacy
      • Specialist Clinics
    • Public Sector
      • Donor Funded Programs
      • Government Programs
  • End User
    • Clinics
      • General Clinics
      • Specialty Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Immunization Centers
    • Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
  • Technology
    • Conjugate
      • Polysaccharide Conjugate
      • Protein Conjugate
    • Inactivated
      • Toxoid
      • Viral
    • Live Attenuated
      • Bacterial
      • Viral
    • Recombinant
      • Mammalian Cell Culture
      • Yeast Based
    • Subunit
      • Peptide Subunit
      • Protein Subunit
  • Age Group
    • Adolescents
    • Children
    • Infants
    • Neonates
    • Toddlers
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • PT Bio Farma (Persero)
  • Sinovac Biotech Ltd.
  • CSL Seqirus Pty Ltd.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pediatric Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Hexavalent
8.3. Monovalent
8.4. Pentavalent
8.5. Quadrivalent
9. Pediatric Vaccines Market, by Disease
9.1. Introduction
9.2. DTP
9.2.1. Diphtheria
9.2.2. Pertussis
9.2.3. Tetanus
9.3. Hepatitis B
9.4. Hib
9.5. Measles
9.6. Pneumococcal
9.7. Polio
9.8. Rotavirus
10. Pediatric Vaccines Market, by Distribution Channel
10.1. Introduction
10.2. Private Sector
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.2.3. Specialist Clinics
10.3. Public Sector
10.3.1. Donor Funded Programs
10.3.2. Government Programs
11. Pediatric Vaccines Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. General Clinics
11.2.2. Specialty Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Immunization Centers
11.5. Pharmacies
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
12. Pediatric Vaccines Market, by Technology
12.1. Introduction
12.2. Conjugate
12.2.1. Polysaccharide Conjugate
12.2.2. Protein Conjugate
12.3. Inactivated
12.3.1. Toxoid
12.3.2. Viral
12.4. Live Attenuated
12.4.1. Bacterial
12.4.2. Viral
12.5. Recombinant
12.5.1. Mammalian Cell Culture
12.5.2. Yeast Based
12.6. Subunit
12.6.1. Peptide Subunit
12.6.2. Protein Subunit
13. Pediatric Vaccines Market, by Age Group
13.1. Introduction
13.2. Adolescents
13.3. Children
13.4. Infants
13.5. Neonates
13.6. Toddlers
14. Americas Pediatric Vaccines Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pediatric Vaccines Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pediatric Vaccines Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. GlaxoSmithKline plc
17.3.3. Merck & Co., Inc.
17.3.4. Sanofi S.A.
17.3.5. Serum Institute of India Private Limited
17.3.6. Bharat Biotech International Limited
17.3.7. PT Bio Farma (Persero)
17.3.8. Sinovac Biotech Ltd.
17.3.9. CSL Seqirus Pty Ltd.
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PEDIATRIC VACCINES MARKET MULTI-CURRENCY
FIGURE 2. PEDIATRIC VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. PEDIATRIC VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PEDIATRIC VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PEDIATRIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PEDIATRIC VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DONOR FUNDED PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 110. CANADA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 111. CANADA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 112. CANADA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 113. CANADA PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. CANADA PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 115. CANADA PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 116. CANADA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 118. CANADA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 119. CANADA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 120. CANADA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. CANADA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 122. CANADA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 123. CANADA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 124. CANADA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 125. CANADA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 126. CANADA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 130. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 132. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 133. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 137. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 140. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 141. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 142. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 143. MEXICO PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 214. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 215. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 216. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 218. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 219. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 221. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 225. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 226. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 227. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 228. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 229. GERMANY PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 231. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 232. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 233. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 235. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 236. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 238. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 240. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 242. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 243. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 244. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 245. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 246. FRANCE PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 264. ITALY PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 265. ITALY PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 266. ITALY PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 267. ITALY PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. ITALY PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 269. ITALY PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 270. ITALY PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. ITALY PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 272. ITALY PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 273. ITALY PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 274. ITALY PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 275. ITALY PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 276. ITALY PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 277. ITALY PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 278. ITALY PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 279. ITALY PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 280. ITALY PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 282. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 283. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 284. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 286. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 287. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 289. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 290. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 294. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 295. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 296. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 297. SPAIN PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 324. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 326. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 328. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 330. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 332. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 334. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 336. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE SECTOR, 2018-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC SECTOR, 2018-2030 (USD MILLION)
TABLE 338. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 339. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 340. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 341. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 342. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 343. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2030 (USD MILLION)
TABLE 344. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 345. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 346. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 348. SOUTH AFRICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 349. DENMARK PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (US

Companies Mentioned

The companies profiled in this Pediatric Vaccines market report include:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • PT Bio Farma (Persero)
  • Sinovac Biotech Ltd.
  • CSL Seqirus Pty Ltd.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 23.83 Billion
Forecasted Market Value ( USD ) by 2030 $ 41.11 Billion
Compound Annual Growth Rate11.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Pediatric Vaccines Market by Vaccine Type, by Technology, by Indication, by Distribution Channel, and by Region - Product Image

Pediatric Vaccines Market by Vaccine Type, by Technology, by Indication, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Pediatric Vaccines Market Report by Type, Technology, Application, and Region 2025-2033 - Product Image

Pediatric Vaccines Market Report by Type, Technology, Application, and Region 2025-2033

  • Report
  • 149 Pages
  • Global
From
Pediatric Vaccine Market Opportunities and Strategies to 2033 - Product Image

Pediatric Vaccine Market Opportunities and Strategies to 2033

  • Report
  • 286 Pages
  • Global
From
Pediatric Vaccine Market Report 2025 - Product Image

Pediatric Vaccine Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Pediatric Vaccine Market

The Pediatric Vaccine market is a subset of the larger Vaccine market, which focuses on the development and distribution of vaccines for children. Vaccines are a critical tool in the prevention of infectious diseases, and the pediatric vaccine market is a key component of the global effort to reduce the burden of disease in children. Vaccines are typically administered to children at a young age, and the pediatric vaccine market is focused on providing safe and effective vaccines to protect children from a variety of diseases. The pediatric vaccine market is highly regulated, with stringent safety and efficacy standards in place to ensure the safety of the vaccines. Vaccines are typically developed and tested in clinical trials before being approved for use in children. Vaccines are also subject to ongoing monitoring and surveillance to ensure their continued safety and effectiveness. The pediatric vaccine market is highly competitive, with a number of companies involved in the development and distribution of vaccines. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.